Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siremadlin in Combination With Venetoclax Plus Azacitidine in Unfit Adult AML
NCT05155709Phase 1Completed
- Sponsor
- Novartis
- Start
- May 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of siremadlin in acute myeloid leukemia (AML) (2 arms), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 28 days and Complete Remission at 196 days. Started May 2022; status: completed.
02
Drugs
siremadlin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05155709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05155709.